Trial Investigates Adding Chemotherapy to Reduce Rapid Progression Risk in Lung Cancer
The HYPERBOLIC trial evaluates whether adding short-course chemotherapy to cemiplimab mitigates the risk of hyperprogressive disease in biomarker-selected lung cancer patients.
Key takeaways
- Standard first-line immune checkpoint inhibitor monotherapy is used for PD-L1-high advanced NSCLC, but up to 30 percent of patients experience early progression or death.
- High baseline levels (30.5 percent or greater) of circulating CD10-negative low-density neutrophils are associated with an increased occurrence of hyperprogressive disease.
- The HYPERBOLIC trial will randomize 74 patients to cemiplimab alone or cemiplimab plus three cycles of platinum-based chemotherapy.
- The primary endpoint is the combined rate of hyperprogressive disease, assessed at week 7, and early death within 12 weeks of treatment start.
- An extensive translational platform will perform multi-omic profiling of tissue, blood, saliva, and stool to study tumor-host dynamics.
Standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) whose tumors express high levels of the biomarker PD-L1—specifically 50 percent or greater—is immune checkpoint inhibitor monotherapy. Although this is standard, up to 30 percent of these patients experience early disease progression or death, which can include cases of hyperprogressive disease where tumor growth rapidly accelerates.
To address this clinical challenge, researchers have designed the HYPERBOLIC trial, a prospective, biomarker-guided study. According to a study protocol published in the journal Clinical Lung Cancer in August 2026, this international, multicenter study is the first prospective clinical trial designed to investigate whether early treatment escalation based on hyperprogressive disease risk can improve outcomes in patients with high PD-L1-expressing non-small cell lung cancer.
The trial focuses on patients who have high baseline levels of specific immune cells called circulating CD10-negative low-density neutrophils, or LDNs. Baseline levels of 30.5 percent or greater of these cells, identified by flow cytometry as CD15-positive and CD11b-positive within the peripheral blood mononuclear cell fraction (with immature cells defined by the loss of CD10), have been associated with an increased occurrence of hyperprogressive disease.
What Happened
The HYPERBOLIC trial (registered as NCT07274384) is a phase 2, randomized, open-label, multicenter, international trial. The study will randomize 74 patients with stage IV non-small cell lung cancer who have both PD-L1 expression of 50 percent or greater and circulating CD10-negative low-density neutrophils of 30.5 percent or greater.
Participants are randomized in a 1:1 ratio to receive either cemiplimab alone or cemiplimab combined with three cycles of platinum-based chemotherapy, followed by cemiplimab maintenance therapy. Randomization is stratified by the Lung Immune Prognostic Index.
The primary endpoint is the combined rate of hyperprogressive disease and early death. Early death is defined as death occurring within 12 weeks of starting treatment without prior radiological evaluation. Hyperprogressive disease is evaluated at the first computed tomography scan at week 7, defined by RECIST version 1.1 criteria as disease progression with a delta tumor growth rate of 50 percent or greater, a tumor growth rate ratio of 2 or greater, or both. Secondary endpoints include hyperprogressive disease rates under alternative definitions, overall survival, progression-free survival, objective response rate, and safety.
What The Evidence Shows
Because the publication outlines the trial protocol, no clinical efficacy or safety results are currently reported. The scientific foundation for the trial relies on previous findings linking high baseline CD10-negative low-density neutrophils (30.5 percent or greater) to increased hyperprogressive disease occurrence, and evidence indicating that combining immunotherapy with platinum-based chemotherapy may reduce this risk. The study also features an extensive translational research platform to study tumor-host dynamic interactions. This platform will perform spatial transcriptomics of tumor tissue, single-cell RNA sequencing of peripheral blood mononuclear cells, circulating-free DNA and plasma factors profiling, and saliva/stool microbiome genomics and metabolomics.
What We Don't Know Yet
As a phase 2 study protocol, there are no treatment outcomes, efficacy data, or safety results currently available. The study is limited by its planned sample size of 74 randomized patients, and the utility of CD10-negative low-density neutrophils as a predictive biomarker for treatment escalation remains unproven until the trial is completed and its data are analyzed.
What Comes Next
The trial is designed to randomize and treat patients according to the protocol. The published source does not report specific dates or timelines for when the trial will complete its randomization, treatment, or translational analyses. Whether this combination strategy successfully reduces the rate of hyperprogressive disease remains an open clinical question.
What This Means
For clinical practice, the HYPERBOLIC trial represents a prospective effort to transition away from a one-size-fits-all approach for PD-L1-high non-small cell lung cancer. If the addition of short-course chemotherapy reduces the rate of rapid progression and early death, this biomarker-guided approach could help clinicians identify high-risk patients at therapy onset and safely escalate their treatment.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42697029/
Questions readers ask
- What is the main objective of the HYPERBOLIC study?
- The HYPERBOLIC trial is designed to evaluate whether adding three cycles of platinum-based chemotherapy to first-line cemiplimab reduces the combined rate of hyperprogressive disease and early death. The study targets patients with stage IV non-small cell lung cancer with PD-L1 expression of 50 percent or greater and high baseline levels of circulating CD10-negative low-density neutrophils.
- How does the study define hyperprogressive disease?
- Hyperprogressive disease is evaluated at the first computed tomography scan at week 7 after starting treatment. Under RECIST version 1.1 criteria, it is defined as disease progression with a delta tumor growth rate of 50 percent or greater, a tumor growth rate ratio of 2 or greater, or both.
- What biomarkers are used to select patients for this trial?
- Patients are selected based on having stage IV non-small cell lung cancer with PD-L1 expression of 50 percent or greater and baseline circulating CD10-negative low-density neutrophils of 30.5 percent or greater. These neutrophils are identified using flow cytometry as CD15-positive and CD11b-positive within the peripheral blood mononuclear cell fraction, with immature cells defined by the loss of CD10.
What this means
For clinical practice, the HYPERBOLIC trial represents a prospective effort to transition away from a one-size-fits-all approach for PD-L1-high non-small cell lung cancer. If the addition of short-course chemotherapy reduces the rate of rapid progression and early death, this biomarker-guided approach could help clinicians identify high-risk patients at therapy onset and safely escalate their treatment.
Limitations and uncertainties
- As a phase 2 study protocol, there are no treatment outcomes, efficacy data, or safety results currently available. The study is limited by its planned sample size of 74 randomized patients, and the utility of CD10-negative low-density neutrophils as a predictive biomarker for treatment escalation remains unproven until the trial is completed and its data are analyzed.
